

Govt augments manufacturing capacity for COVAXIN production

16 April 2021 | News

3 public sectors companies are being supported to increase the capacity of vaccine production



As a part government's augmentation plan, capacities of Bharat Biotech Limited, Hyderabad as well as other public sector manufacturers are being upgraded with required infrastructure and technology.

Financial support is being provided as grant from GoI to the tune of appx Rs 65 Cr to Bharat Biotech's new Bangalore facility which is being repurposed to increase the capacity of vaccine production.

3 public sectors companies are also being supported to increase the capacity of vaccine production.

The Department of Science & Technology (DST), GoI, has granted approval to Haffkine Institute to produce Bharat Biotech's Covaxin vaccine on a transfer of technology basis.

Last month Maharashtra Chief Minister Uddhav Thackeray in a video conference with the Prime Minister, Narendra Modi had urged the centre to grant permission to Haffkine Bio-Pharmaceutical Corporation Limited to manufacture the COVID-19 vaccine.

Financial support as grant from GoI to the tune of appx Rs 65 Cr will be provided for this facility to be made ready for manufacturing. The Haffkine Biopharmaceuticals Ltd had asked for around 12 months to complete this task. However, the Central government has asked them to expedite and complete the task urgently within 6 months. The facility will have a capacity of 20 million doses per month, once functional.

Indian Immunologicals Limited (IIL), Hyderabad –A facility under National Dairy Development Board and Bharat Immunologicals and Biologicals Limited (BIBCOL), Bulandshahr a CPSE under Department of Biotechnology, Govt of India will also be supported to prepare their facility to provide 10-15 million doses per month by Aug - Sep 2021.